We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site

Discovering Multiple Pathways to Drug Resistance in Melanoma Cells

In a study published in Nature Communications, researchers from the California Institute of Technology utilized IsoPlexis’ Single-Cell Proteomics and Single-Cell Metabolomics to outline an approach for capturing the diverse range of trajectories that individual cells can take en route to drug resistance.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Using unique single-cell functional proteomics and metabolomics to track cellular states
Predicting multiple pathways of resistance with functional phenotyping
How characterizing functional diversity can lead to more effective therapeutic combinations
A Deeper Look

More about this

Understanding Functional Adaptations to Predict Effective Therapeutic Combinations

Cancer cells constantly evolve, regularly adopting new states in response to acute and chronic stimuli, posing a great challenge for treatment, as cells that are initially responsive to pharmacological agents can quickly adopt drug-resistant states through both genetic and non-genetic mechanisms.

Researchers used IsoPlexis’ Single-Cell Proteomics and Single-Cell Metabolomics to show that cancer cell responses to a common stimulus may entail multiple divergent functional pathways while still resulting in the same genomic phenotype.

Download this Paper Summary to learn more!

Get the